GlassScriptPhysician profile
Andrea Gonzalez
NPI 1336176403
$17,070.79
in general payments reported to CMS, 2019-2025
25 companies · $73.50 in 2025
The $73.50 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $714 · 2020: $587 · 2021: $454 · 2022: $572 · 2023: $13K · 2024: $1,466 · 2025: $73.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $2,210 · Education: $34.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,500.00 |
| Food and Beverage | $2,209.52 |
| Education | $34.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chromacode, INC | $12,500.00 | 2023 | |
| Viiv Healthcare Company | $1,606.40 | 2019-2024 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $527.15 | 2019-2024 | Delstrigo, Pifeltro, Dificid |
| Gilead Sciences, INC. | $477.24 | 2019-2024 | |
| Insmed, INC. | $280.31 | 2019-2025 | Arikayce |
| Melinta Therapeutics, LLC | $204.26 | 2022-2025 | Rezzayo, Kimyrsa, Vabomere |
| Janssen Biotech, INC. | $192.70 | 2019-2023 | Symtuza |
| La Jolla Pharmaceutical Company | $168.19 | 2021-2025 | Xerava, Xacduro, Giapreza |
| Abbvie INC. | $145.70 | 2021-2024 | |
| Theratechnologies INC. | $141.52 | 2022-2024 | Egrifta, Trogarzo |
| Astellas Pharma US INC | $139.32 | 2019-2024 | Cresemba |
| Tetraphase Pharmaceuticals, INC. | $126.13 | 2019-2020 | |
| Shionogi INC | $104.29 | 2023-2024 | Fetroja |
| Paratek Pharmaceuticals, INC. | $99.09 | 2020-2024 | Nuzyra |
| Pfizer INC. | $74.62 | 2020-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $47.76 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $42.13 | 2023-2024 | Lupkynis |
| Pharming Healthcare, INC. | $40.86 | 2022-2024 | Ruconest |
| Hospira, INC. | $38.18 | 2022-2023 | |
| Octapharma USA, INC. | $36.60 | 2024 | Panzyga |
| Glaxosmithkline, LLC. | $20.84 | 2024 | Shingrix, Arexvy |
| Aimmune Therapeutics, INC. | $17.58 | 2024 | |
| Abiomed | $15.77 | 2025 | |
| Vbi Vaccine (Delaware) INC. | $12.70 | 2022 | |
| Abbott Laboratories | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.